4//SEC Filing
Elvig Mark F 4
Accession 0001000229-19-000002
CIK 0001000229other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 4:08 PM ET
Size
8.8 KB
Accession
0001000229-19-000002
Insider Transaction Report
Form 4
Elvig Mark F
VP, Counsel & Secretary
Transactions
- Exercise/Conversion
Common Shares
2018-12-31+3,000→ 25,054 total - Tax Payment
Common Shares
2018-12-31$59.66/sh−731$43,611→ 24,323 total - Exercise/Conversion
Performance Shares
2018-12-31−3,000→ 0 totalExercise: $0.00→ Common Shares (3,000 underlying)
Holdings
- 2,568(indirect: By 401(k))
Common Shares
Footnotes (1)
- [F1]These awards vested at the end of a three-year performance period that began on January 1, 2016 and ended on December 31, 2018 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period.
Documents
Issuer
CORE LABORATORIES N V
CIK 0001000229
Entity typeother
Related Parties
1- filerCIK 0001435153
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 4:08 PM ET
- Size
- 8.8 KB